ROLE OF CYTOKINES(INF- Γ, IL-6, IL-10) IN THE PATHOGENESIS OF AUTOIMMUNE TYPE I DIABETES MELLITUS
Journal Title: European Journal of Pharmaceutical and Medical Research - Year 2019, Vol 6, Issue 1
Abstract
Type I diabetes mellitus is an autoimmune disease; it is one of most serious and common metabolic disorders in children and adolescents, in which the body immune system destroys the insulin releasing beta cells. Thus, the body cells cannot absorb glucose. Cytokines play a major role in the pathogenesis of autoimmune type I diabetes and in the initiation of β-cell damaging process. The objective of this study is to get more understanding about the role of cytokines in the development of beta cell destruction and immune state in T1DM patient, by measuring the IFN-γ, IL-6 and IL-10. A total of sixty patients with long standing autoimmune T1DM (diagnosed more than one year) were included in the study. Twenty eight healthy control subjects had the measurement of serum IL-6, IL-10 and IFN-γ by enzyme linked immunosorbent assay (ELISA) technique. Higher serum levels of IL-6 and IFN-γ were observed in the patients (224.02, 394.34 pg/ml respectively) compared to controls (164.65, 264.07 pg/ml respectively). The statistical analysis showed a significant difference between patients and controls (P= 0.0001, 0.017 respectively). A difference of the mean IL-6 concentration appears between patients in two age groups in T1DM age (1 -10 y) (P= 0.085). No significant differences appear in the mean between patients and controls for BMI and age (p= 0.865, 0.149 respectively). No significant difference appear in the serum level IL-6, IL.10 and IFN-γ between patients divided into two group according HbA1c (T1DM controlled) and (T1DM uncontrolled) (p=0.604, 0.423, 0.590). In long standing patients with autoimmune type I diabetes mellitus, clinical significant elevation in serum levels of IFN-γ and IL-6 while IL-10 serum level begin decline. A difference of mean IL-6 concentration appears between patients in both age groups T1DM age (1 -10 y). No significant differences appear in the mean serum concentrations of IFN-γ, IL.10 and IL-6 between patient and control for BMI and age. No significant difference appear in the serum level IFN-γ, IL-10 and IL-6 between patients divided into two groups according HbA1c (T1DM controlled) and (T1DM uncontrolled).
Authors and Affiliations
Husam A. Alaebe
Keywords
Related Articles
- EP ID EP672396
- DOI -
- Views 138
- Downloads 0
THE PREVALENCE OF HCV INFECTION AMONG DIALYSIS PATIENTS AT KHMC
Aim: The aim of this study is to evaluate the prevalence of HCV infection, in relation to age and sex, among haemodialysis patients at KHMC. Materials and methods: This study was conducted in the period between January 2...
KNOWLEDGE AND ATTITUDES TOWARDS MAINTENANCE OF GOOD ORAL HEALTH AND UTILIZATION OF DENTAL HEALTH SERVICES IN SAKAKA AL JOUF, A CROSS SECTIONAL DISCRIPTIVE STUDY
Objective: The main objective of this study is to assess the knowledge and attitudes of adults towards maintenance of good oral health and utilization of dental health services available in Sakaka Al Jouf. Methodology: U...
ROLE OF CYTOKINES(INF- Γ, IL-6, IL-10) IN THE PATHOGENESIS OF AUTOIMMUNE TYPE I DIABETES MELLITUS
Type I diabetes mellitus is an autoimmune disease; it is one of most serious and common metabolic disorders in children and adolescents, in which the body immune system destroys the insulin releasing beta cells. Thus, th...
PERCEPTION AND ACCEPTABILITY OF PREGNANT WOMEN TOWARDS CAESAREAN SECTION IN NIGERIA
Background: Caesarean section remains the most common major operation performed on women worldwide and rate is increasing. Mortality and morbidity from pregnancy and labour related causes have been observed to be high in...
DESIGN AND CHARACTERIZATION OF TENOXICAM MICROCAPSULES PREPARED BY IONOTROPIC GELATION AND IN VIVO EVALUATION OF ULCEROGENIC ACTIVITY IN RATS
The formulation of tenoxicam using biodegradable and biocompatible polymers in the form of microcapsules is expected to decrease gastrointestinal side effects. Different microcapsule formulation of tenoxicam were prepare...